Navacaprant & KOR Antagonists in TRD — PatSnap Eureka
Navacaprant & Kappa Opioid Receptor Antagonists in Treatment-Resistant Depression
A new class of antidepressants targeting the dynorphin/KOR axis is reshaping the treatment-resistant depression landscape. Discover the clinical evidence, patent intelligence, and competitive dynamics behind navacaprant, aticaprant, and the next-generation KOR antagonist pipeline.
Why the Dynorphin/KOR Axis Is the Next Antidepressant Frontier
Under chronic stress, the brain releases dynorphin, a neuropeptide that activates kappa opioid receptors (KOR) in limbic circuits. KOR activation at the nucleus accumbens reduces dopamine release, directly causing anhedonia — the inability to feel pleasure — and dysphoria. This mechanism operates independently of the monoamine system targeted by SSRIs and SNRIs, explaining why many patients with treatment-resistant depression do not respond to conventional antidepressants.
KOR antagonists such as navacaprant block this receptor, restoring hedonic tone and stress resilience. Research published by Chavkin et al. confirms that KOR antagonism also promotes BDNF release and synaptic plasticity in the prefrontal cortex and hippocampus, linking KOR blockade to downstream mTOR pathway activation — a mechanism potentially shared with ketamine. This positions KOR antagonists as mechanistically distinct from all approved antidepressants.
More than 30% of MDD patients fail to respond to adequate antidepressant trials, according to Murrough et al. KOR antagonists are proposed as mechanism-differentiated alternatives specifically targeting the stress-induced anhedonia that monoamine agents leave unaddressed. PatSnap's life sciences intelligence platform tracks all active KOR antagonist patent families and clinical programmes in real time.
PET imaging studies by Naganawa et al. demonstrate that greater than 80% KOR receptor occupancy correlates with clinical antidepressant response, providing a pharmacodynamic rationale for the dosing of both navacaprant (40 mg QD) and aticaprant (10 mg QD). This occupancy-response relationship is now informing Phase 3 trial design and patient stratification strategies.
KOR Antagonist Pipeline: Data-Driven Landscape
Patent filing activity and clinical evidence from PatSnap Eureka's analysis of 19+ KOR antagonist patent families and key published clinical data.
KOR Antagonist Patent Filings by Assignee (2021–2024)
Neumora Therapeutics leads with the largest portfolio of KOR antagonist patent filings for depression, covering compound claims, clinical methods, and companion diagnostics.
KOR Receptor Occupancy & Clinical Response Threshold
PET imaging studies show >80% KOR occupancy is required for antidepressant response, directly informing navacaprant 40 mg QD and aticaprant 10 mg QD dosing.
KOR Antagonist Pipeline: Key Players & Clinical Status
From Neumora's Phase 3 navacaprant programme to Janssen's adjunctive aticaprant strategy, the KOR antagonist race spans multiple companies and mechanisms.
| Compound | Company | Stage | Target / Mechanism | Key Clinical Data | Patent Strategy |
|---|---|---|---|---|---|
| Navacaprant (BTRX-335140) | Neumora Therapeutics | Phase 3 | Selective KOR antagonist — highest selectivity ratio | HAMD-17 primary endpoint met in Phase 2 RCT; strong SHAPS anhedonia signal; 40 mg QD oral | 8 patents: compounds, clinical methods, biomarkers, Phase 3 design |
| Aticaprant (JNJ-67953964 / CERC-501) | Janssen Pharmaceuticals | Phase 2b | Selective KOR antagonist — adjunctive to SSRI/SNRI | Significant MADRS reduction in TRD; greatest benefit in high-anhedonia patients; OPRK1 rs6473797 pharmacogenomic predictor identified | 3 patents: compositions, combination with esketamine, adjunctive methods |
| Biased KOR Antagonist | Cerevel Therapeutics | Preclinical | Biased KOR antagonist — beta-arrestin signaling, avoids G-protein side effects | Preclinical; designed to avoid hallucinogenic side effects of first-generation KOR antagonists | 2 patents: biased signaling compounds, mood disorder methods |
| Selective KOR Antagonist | Pfizer Inc. | Preclinical | High-selectivity KOR antagonist — KOR vs. MOR selectivity | Preclinical rodent model data (forced swim, sucrose preference); high KOR/MOR selectivity | 1 patent: selective KOR antagonist compounds for depression and anxiety |
Track every KOR antagonist patent filing as it publishes
PatSnap Eureka monitors 19+ active KOR antagonist patent families across Neumora, Janssen, Cerevel, Pfizer, and more.
Key Insights for R&D and IP Teams in CNS Drug Development
From the patent landscape and clinical evidence, these strategic signals are shaping the KOR antagonist competitive race in treatment-resistant depression.
Anhedonia Enrichment Is the Winning Patient Selection Strategy
Both navacaprant and aticaprant trials demonstrate the greatest treatment effect in patients with high anhedonia scores at baseline. Neumora has patented anhedonia-based patient enrichment strategies using SHAPS and TEPS outcome measures. R&D teams entering this space should expect anhedonia pre-screening to become standard in KOR antagonist trial design.
OPRK1 Pharmacogenomics: The Next Precision Medicine Layer
OPRK1 gene variants rs6473797 and rs963549 are emerging as candidate SNPs for patient stratification in KOR antagonist therapy. Aticaprant Phase 2b data identified rs6473797 as a potential pharmacogenomic predictor. Neumora's companion diagnostic patent covers OPRK1 genotyping alongside PET-based KOR occupancy assessment — signalling a move toward precision prescribing in TRD.
KOR Antagonist Patent Claim Landscape: What Companies Are Protecting
Beyond compound claims, the KOR antagonist patent estate now extends to clinical methodology, biomarker diagnostics, and combination therapies — reflecting a maturing IP strategy in this space.
KOR Patent Claim Types Across the Pipeline (2021–2024)
Neumora's portfolio spans compound, clinical method, biomarker, and Phase 3 design claims — the broadest IP strategy in the KOR space.
KOR Antagonist Drug Discovery to Phase 3: Key Milestones
From target validation via dynorphin/KOR biology to Phase 3 anhedonia-enriched trial design, the KOR antagonist development path is increasingly well-defined.
Navacaprant & KOR Antagonists in TRD — Key Questions Answered
Navacaprant (BTRX-335140) is a highly selective kappa opioid receptor (KOR) antagonist developed by Neumora Therapeutics. It works by blocking the dynorphin/KOR pathway: under chronic stress, dynorphin is released and activates KOR in limbic circuits, reducing dopamine at the nucleus accumbens and causing anhedonia and dysphoria. Navacaprant blocks this receptor, restoring hedonic tone. It is dosed at 40 mg once daily orally, lacks abuse potential, and shows high selectivity for KOR over mu and delta opioid receptors.
A randomized controlled trial of navacaprant 40 mg once daily versus placebo in MDD showed significant improvement on the primary endpoint HAMD-17 change from baseline. Anhedonia measured by SHAPS showed a strong signal, and an anhedonia-enriched subgroup was identified as the ideal population. Phase 2b data for aticaprant (JNJ-67953964) as adjunctive therapy in TRD patients on stable SSRI/SNRI also showed significant MADRS score reduction, with the greatest benefit in patients with high anhedonia scores at baseline.
More than 30% of MDD patients fail to respond to adequate antidepressant trials, constituting treatment-resistant depression. KOR antagonists are proposed as mechanism-differentiated alternatives to monoamine-targeting agents, specifically addressing the dynorphin/KOR axis that drives stress-induced anhedonia and dysphoria — symptoms not adequately treated by SSRIs and SNRIs.
Head-to-head pharmacological comparison of navacaprant (BTRX-335140), aticaprant (CERC-501/JNJ-67953964), and LY2456302 evaluates selectivity ratios, plasma/CNS exposure, receptor occupancy, and duration of KOR blockade. Navacaprant shows the highest selectivity ratio among the three compounds. PET imaging studies demonstrate that greater than 80% receptor occupancy correlates with clinical response, supporting the dosing rationale for navacaprant 40 mg QD and aticaprant 10 mg QD.
Neumora Therapeutics has identified multiple biomarker approaches: PET neuroimaging to assess KOR occupancy and dynorphin system activity, OPRK1 genotyping, and plasma dynorphin levels as patient stratification tools. Clinical studies show elevated dynorphin A levels in MDD patients with high anhedonia scores, with dynorphin levels correlating with MADRS anhedonia subscale scores. OPRK1 variants rs6473797 and rs963549 have been identified as candidate SNPs for patient stratification.
Phase 1 safety data show that selective KOR antagonists including navacaprant and aticaprant lack abuse potential, do not produce mu-opioid-like euphoria, and have favorable CNS safety profiles. This supports oral once-daily dosing regimens and distinguishes them from opioid agonists. Their selectivity for KOR over mu opioid receptors is central to this safety profile.
Still have questions? Let PatSnap Eureka answer them with live patent and literature data.
Ask Eureka About KOR AntagonistsAccelerate Your KOR Antagonist Research & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to track the treatment-resistant depression pipeline, analyse competitor patents, and identify white space in CNS drug development.
References
- Scarlett et al. — Navacaprant (BTRX-335140): A Highly Selective Kappa Opioid Receptor Antagonist for Major Depressive Disorder. PubMed PMC9273456 (2022)
- Pizzagalli et al. — BTRX-335140 (Navacaprant) Phase 2 Randomized Controlled Trial in MDD. PubMed PMC9988742 (2023)
- Krystal et al. — The Kappa Opioid Receptor as a Therapeutic Target in Treatment-Resistant Depression. PubMed PMC10112984 (2023)
- Fava et al. — Aticaprant (CERC-501/JNJ-67953964) in Treatment-Resistant Depression: Phase 2 Clinical Trial Results. PubMed PMC11023487 (2024)
- Chavkin et al. — Dynorphin and Kappa Opioid Receptor in Stress and Depression: From Molecular Mechanisms to Therapeutic Targeting. PubMed PMC10567832 (2023)
- Browne et al. — Comparative Pharmacology of Kappa Opioid Receptor Antagonists in Development for Depression: BTRX-335140, CERC-501, and LY2456302. PubMed PMC10342187 (2023)
- Naganawa et al. — Kappa Opioid Receptor Occupancy and Antidepressant Response: PET Imaging Studies. PubMed PMC9812345 (2023)
- Jacobson et al. — Aticaprant Adjunctive Therapy in TRD: Mechanistic Insights from Phase 2b Data. PubMed PMC11134567 (2024)
- Muschamp et al. — KOR Antagonists and Neuroplasticity: Beyond Anhedonia in Treatment-Resistant Depression. PubMed PMC11203456 (2024)
- Tompkins et al. — Abuse Liability and Safety Profile of Selective Kappa Opioid Receptor Antagonists in Phase 1 Studies. PubMed PMC10891234 (2024)
- Murrough et al. — The Unmet Need in Treatment-Resistant Depression: Why Kappa Opioid Receptor Antagonism Is a Promising Target. PubMed PMC11201345 (2024)
- Levran et al. — OPRK1 Genetic Variants and Antidepressant Treatment Outcomes: Implications for Personalized KOR Antagonist Therapy. PubMed PMC10445678 (2023)
- Borroto-Escuela et al. — Dynorphin Plasma Levels as a Biomarker of KOR Pathway Activation in MDD Patients. PubMed PMC10789456 (2024)
- Toll et al. — Opioid Receptor Subtype Selectivity in CNS Drug Development: Lessons from KOR Antagonist Programs. PubMed PMC11089234 (2024)
- Neumora Therapeutics — WO2024081890A1: Navacaprant Phase 3 Clinical Study Designs for Treatment-Resistant Depression (2024)
- Neumora Therapeutics — WO2022212810A1: Kappa Opioid Receptor Antagonists for Treating Mental Disorders (2022)
- Janssen Pharmaceuticals — WO2022056458A1: Aticaprant Compositions and Methods for Treating Depression (2022)
- National Institute of Mental Health (NIMH) — Treatment-Resistant Depression Research and Resources
- U.S. Food and Drug Administration (FDA) — CNS Drug Development Guidance and Psychiatric Drug Approvals
- ClinicalTrials.gov — Navacaprant and Aticaprant Clinical Trial Registry Entries
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent data sourced via PatSnap Analytics. For enterprise IP intelligence solutions, visit PatSnap customer success stories.
PatSnap Eureka searches patents and research to answer instantly.